SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
A Cost-Effectiveness Analysis of Nivolumab versus Docetaxel for Advanced Nonsquamous NSCLC Including PD-L1 Testing
6 references·1 citing·30 second hop
A Cost-Effectiveness Analysis of Nivolumab versus Docetaxel for Advanced Nonsquamous NSCLC Including PD-L1 Testing (2016)A Cost-Effectiveness Analysis of Nivoluma…Pricing in the Market for Anticancer Drugs (2015)Pricing in the Market for Ant…Individual Responsibility and Community Solidarity — The Swiss Health Care System (2015)Individual Responsibility and…American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options (2015)American Society of Clinical …A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) (2015)A standardised, generic, vali…High Cancer Drug Prices in the United States: Reasons and Proposed Solutions (2014)High Cancer Drug Prices in th…Willingness to Pay for a Quality-adjusted Life Year (2000)Willingness to Pay for a Qual…Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib for Patients With Unresectable or Metastatic Hepatocellular Carcinoma (2021)Cost-effectiveness of Atezoli…Contingent Valuation: Is Some Number Better than No Number? (1994)Cost-Effectiveness in Health and Medicine (1996)Cost-of-illness studies: concepts, scopes, and methods (2014)Thresholds for the cost–effectiveness of interventions: alternative approaches (2014)Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold (2015)Social Security Bulletin (2018)Cost Sharing and Adherence to Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia (2013)The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts (2013)The Price of Inequality (2013)Addressing Financial Barriers to Patient Participation in Clinical Trials: ASCO Policy Statement (2018)Randomized, Controlled Trials, Observational Studies, and the Hierarchy of Research Designs (2000)GRADE guidelines: 3. Rating the quality of evidence (2011)Economic burden of cancer across the European Union: a population-based cost analysis (2013)Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received (2016)Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13 (2017)The high price of anticancer drugs: origins, implications, barriers, solutions (2017)Net Health Benefits (1998)Projections of the Cost of Cancer Care in the United States: 2010-2020 (2011)The Financial Toxicity of Cancer Treatment: A Pilot Study Assessing Out-of-Pocket Expenses and the Insured Cancer Patient's Experience (2013)Essential medicines for universal health coverage (2016)Financial Hardships Experienced by Cancer Survivors: A Systematic Review (2016)Mental Accounting and Consumer Choice (1985)Fairness as a Constraint on Profit Seeking: Entitlements in the Market (2000)Mental Accounting and Consumer Choice (2008)Financial toxicity in cancer care: Prevalence, causes, consequences, and reduction strategies (2019)How Much Does It Cost to Research and Develop a New Drug? A Systematic Review and Assessment (2021)Recommendations of the Panel on Cost-Effectiveness in Health and Medicine (1996)Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement (2013)Updating Cost-Effectiveness — The Curious Resilience of the $50,000-per-QALY Threshold (2014)Equity in access to COVID-19 testing for undocumented migrants and homeless persons during the initial phase of the pandemic (2021)
this work references cited by second hop

References

  • 2015American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options916 cited
  • 2000Willingness to Pay for a Quality-adjusted Life Year849 cited
  • 2015A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)817 cited
  • 2015Pricing in the Market for Anticancer Drugs452 cited
  • 2014High Cancer Drug Prices in the United States: Reasons and Proposed Solutions114 cited
  • 2015Individual Responsibility and Community Solidarity — The Swiss Health Care System89 cited

Cited by

  • 2021Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib for Patients With Unresectable or Metastatic Hepatocellular Carcinoma80 cited

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work